229 related articles for article (PubMed ID: 37465925)
1. Mirikizumab for the treatment of moderate to severe ulcerative colitis.
Hanzel J; Ma C; Jairath V
Immunotherapy; 2023 Oct; 15(15):1199-1208. PubMed ID: 37465925
[TBL] [Abstract][Full Text] [Related]
2. Mirikizumab: First Approval.
Keam SJ
Drugs; 2023 Jul; 83(11):1045-1052. PubMed ID: 37389706
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
[TBL] [Abstract][Full Text] [Related]
4. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes.
Magro F; Pai RK; Kobayashi T; Jairath V; Rieder F; Redondo I; Lissoos T; Morris N; Shan M; Park M; Peyrin-Biroulet L
J Crohns Colitis; 2023 Oct; 17(9):1457-1470. PubMed ID: 37057827
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748
[TBL] [Abstract][Full Text] [Related]
6. Anti-interleukin-23 agents for the treatment of ulcerative colitis.
Hanžel J; D'Haens GR
Expert Opin Biol Ther; 2020 Apr; 20(4):399-406. PubMed ID: 31760827
[No Abstract] [Full Text] [Related]
7. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G; Dubinsky M; Kobayashi T; Irving PM; Howaldt S; Pokrotnieks J; Krueger K; Laskowski J; Li X; Lissoos T; Milata J; Morris N; Arora V; Milch C; Sandborn W; Sands BE;
N Engl J Med; 2023 Jun; 388(26):2444-2455. PubMed ID: 37379135
[TBL] [Abstract][Full Text] [Related]
8. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE
BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911
[TBL] [Abstract][Full Text] [Related]
9. Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study.
Steere B; Schmitz J; Powell N; Higgs R; Gottlieb K; Liu Y; Jia B; Tuttle JL; Sandborn WJ; Sands BE; D'Haens G; Reinisch W; Krishnan V
Clin Transl Gastroenterol; 2023 Jul; 14(7):e00578. PubMed ID: 36881820
[TBL] [Abstract][Full Text] [Related]
10. Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis.
Choi D; Sheridan H; Bhat S
Ann Pharmacother; 2024 Feb; ():10600280241229742. PubMed ID: 38344998
[TBL] [Abstract][Full Text] [Related]
11. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.
Chua L; Friedrich S; Zhang XC
Clin Pharmacokinet; 2023 Oct; 62(10):1479-1491. PubMed ID: 37610533
[TBL] [Abstract][Full Text] [Related]
12. Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
D'Haens G; Higgins PDR; Peyrin-Biroulet L; Sands BE; Lee S; Moses RE; Redondo I; Escobar R; Gibble TH; Keohane A; Morris N; Zhang X; Arora V; Kobayashi T
Inflamm Bowel Dis; 2024 Jan; ():. PubMed ID: 38271613
[TBL] [Abstract][Full Text] [Related]
13. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23.
Steere B; Beidler C; Martin A; Bright S; Kikly K; Benschop RJ
J Pharmacol Exp Ther; 2023 Nov; 387(2):180-187. PubMed ID: 37714687
[TBL] [Abstract][Full Text] [Related]
14. Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.
Sands BE; Feagan BG; Hunter Gibble T; Traxler KA; Morris N; Eastman WJ; Schreiber S; Jairath V; Long MD; Armuzzi A
Crohns Colitis 360; 2023 Oct; 5(4):otad070. PubMed ID: 38034882
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapies for ulcerative colitis.
Hanzel J; Hulshoff MS; Grootjans J; D'Haens G
Expert Rev Clin Immunol; 2022 May; 18(5):513-524. PubMed ID: 35477319
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease.
Almradi A; Hanzel J; Sedano R; Parker CE; Feagan BG; Ma C; Jairath V
BioDrugs; 2020 Dec; 34(6):713-721. PubMed ID: 33105016
[TBL] [Abstract][Full Text] [Related]
17. Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission.
Dubinsky MC; Clemow DB; Hunter Gibble T; Li X; Vermeire S; Hisamatsu T; Travis SPL
Crohns Colitis 360; 2023 Jan; 5(1):otac044. PubMed ID: 36777368
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
Sands BE; Peyrin-Biroulet L; Kierkus J; Higgins PDR; Fischer M; Jairath V; Hirai F; D'Haens G; Belin RM; Miller D; Gomez-Valderas E; Naegeli AN; Tuttle JL; Pollack PF; Sandborn WJ
Gastroenterology; 2022 Feb; 162(2):495-508. PubMed ID: 34748774
[TBL] [Abstract][Full Text] [Related]
19. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
[TBL] [Abstract][Full Text] [Related]
20. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
